These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 24703097)

  • 21. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
    Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J
    J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis.
    Nakajima H; Motomura M; Tanaka K; Fujikawa A; Nakata R; Maeda Y; Shima T; Mukaino A; Yoshimura S; Miyazaki T; Shiraishi H; Kawakami A; Tsujino A
    BMJ Open; 2015 Apr; 5(4):e007766. PubMed ID: 25838512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MOG antibody-related disorders: common features and uncommon presentations.
    Cobo-Calvo Á; Ruiz A; D'Indy H; Poulat AL; Carneiro M; Philippe N; Durand-Dubief F; Deiva K; Vukusic S; Desportes V; Marignier R
    J Neurol; 2017 Sep; 264(9):1945-1955. PubMed ID: 28770374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
    de Seze J
    Curr Opin Neurol; 2019 Feb; 32(1):111-114. PubMed ID: 30562266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China.
    Song H; Zhou H; Yang M; Tan S; Wang J; Xu Q; Liu H; Wei S
    Br J Ophthalmol; 2019 Jun; 103(6):831-836. PubMed ID: 30049802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease.
    Lechner C; Baumann M; Hennes EM; Schanda K; Marquard K; Karenfort M; Leiz S; Pohl D; Venkateswaran S; Pritsch M; Koch J; Schimmel M; Häusler M; Klein A; Blaschek A; Thiels C; Lücke T; Gruber-Sedlmayr U; Kornek B; Hahn A; Leypoldt F; Sandrieser T; Gallwitz H; Stoffels J; Korenke C; Reindl M; Rostásy K
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):897-905. PubMed ID: 26645082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients.
    Zhao Y; Tan S; Chan TCY; Xu Q; Zhao J; Teng D; Fu H; Wei S
    Br J Ophthalmol; 2018 Oct; 102(10):1372-1377. PubMed ID: 29363529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis.
    Martinez-Hernandez E; Sepulveda M; Rostásy K; Höftberger R; Graus F; Harvey RJ; Saiz A; Dalmau J
    JAMA Neurol; 2015 Feb; 72(2):187-93. PubMed ID: 25506781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.
    Höftberger R; Sepulveda M; Armangue T; Blanco Y; Rostásy K; Calvo AC; Olascoaga J; Ramió-Torrentà L; Reindl M; Benito-León J; Casanova B; Arrambide G; Sabater L; Graus F; Dalmau J; Saiz A
    Mult Scler; 2015 Jun; 21(7):866-874. PubMed ID: 25344373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.
    Tajfirouz DA; Bhatti MT; Chen JJ
    Curr Neurol Neurosci Rep; 2019 Nov; 19(12):100. PubMed ID: 31773369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.
    Mariotto S; Ferrari S; Monaco S; Benedetti MD; Schanda K; Alberti D; Farinazzo A; Capra R; Mancinelli C; De Rossi N; Bombardi R; Zuliani L; Zoccarato M; Tanel R; Bonora A; Turatti M; Calabrese M; Polo A; Pavone A; Grazian L; Sechi G; Sechi E; Urso D; Delogu R; Janes F; Deotto L; Cadaldini M; Bianchi MR; Cantalupo G; Reindl M; Gajofatto A
    J Neurol; 2017 Dec; 264(12):2420-2430. PubMed ID: 29063242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China.
    Zhao G; Chen Q; Huang Y; Li Z; Sun X; Lu P; Yan S; Wang M; Tian G
    J Neurol; 2018 Jan; 265(1):33-40. PubMed ID: 29101456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between NMO-antibody and anti-MOG antibody in optic neuritis.
    Kezuka T; Usui Y; Yamakawa N; Matsunaga Y; Matsuda R; Masuda M; Utsumi H; Tanaka K; Goto H
    J Neuroophthalmol; 2012 Jun; 32(2):107-10. PubMed ID: 22157536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.
    Pröbstel AK; Rudolf G; Dornmair K; Collongues N; Chanson JB; Sanderson NS; Lindberg RL; Kappos L; de Seze J; Derfuss T
    J Neuroinflammation; 2015 Mar; 12():46. PubMed ID: 25889963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prognostic value of aquaporin-4 antibody in patients of inflammatory demyelinating diseases in central nervous system].
    Yang Y; Wu WP; Huang DH; Wu L
    Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(43):3032-5. PubMed ID: 23328372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lower frequency of antibodies to MOG in Brazilian patients with demyelinating diseases: An ethnicity influence?
    Papais-Alvarenga RM; Neri VC; de Araújo E Araújo ACR; da Silva EB; Alvarenga MP; Pereira ABCNDG; Brandão AC; Alvarenga-Filho H; Guimarães MPM; Marignier R; Barros PO; Bento CM; Vasconcelos CCF
    Mult Scler Relat Disord; 2018 Oct; 25():87-94. PubMed ID: 30056361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases.
    Mariotto S; Gajofatto A; Batzu L; Delogu R; Sechi G; Leoni S; Pirastru MI; Bonetti B; Zanoni M; Alberti D; Schanda K; Monaco S; Reindl M; Ferrari S
    Neurology; 2019 Nov; 93(20):e1867-e1872. PubMed ID: 31645473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical spectrum of anti-MOG associated acquired demyelinating disorders: Three case-reports.
    Bellinvia A; Pastò L; Razzolini L; Fratangelo R; Prestipino E; Fonderico M; Tudisco L; Amato MP
    Mult Scler Relat Disord; 2019 Aug; 33():51-54. PubMed ID: 31152967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen.
    Jarius S; Probst C; Borowski K; Franciotta D; Wildemann B; Stoecker W; Wandinger KP
    J Neurol Sci; 2010 Apr; 291(1-2):52-6. PubMed ID: 20117794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiologic and Clinical Characteristics of Optic Neuritis in Japan.
    Ishikawa H; Kezuka T; Shikishima K; Yamagami A; Hiraoka M; Chuman H; Nakamura M; Hoshi K; Goseki T; Mashimo K; Mimura O; Yoshitomi T; Tanaka K;
    Ophthalmology; 2019 Oct; 126(10):1385-1398. PubMed ID: 31196727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.